Bausch Health Companies (BHC) to Release Earnings on Thursday

Bausch Health Companies (NYSE:BHC) is scheduled to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.74 per share for the quarter. Bausch Health Companies has set its FY 2024 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Bausch Health Companies (NYSE:BHC) last posted its earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. Bausch Health Companies’s revenue for the quarter was up 9.8% compared to the same quarter last year. During the same period last year, the firm posted $1.02 earnings per share. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Bausch Health Companies Stock Up 0.4 %

Bausch Health Companies stock opened at $8.57 on Thursday. Bausch Health Companies has a 52-week low of $5.57 and a 52-week high of $11.46. The firm’s fifty day moving average is $9.29 and its 200 day moving average is $8.16. The company has a market cap of $3.13 billion, a price-to-earnings ratio of -5.29 and a beta of 0.85.

Analysts Set New Price Targets

BHC has been the topic of several recent research reports. Jefferies Financial Group decreased their target price on shares of Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, February 20th. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Finally, Royal Bank of Canada lowered their price objective on shares of Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating for the company in a research report on Tuesday.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.